Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

TheMotleyFool

0 0

Why Dicerna Pharmaceuticals Stock Is Tumbling on FridayPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png

Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA), a clinical-stage biopharmaceutical company, are tanking after a phase 2 clinical trial readout with the company's lead candidate, nedosiran. Investors left wondering about the company's next move pushed the stock 27.4% lower as of 2:22 p.m. EDT on Friday.

Dicerna Pharmaceuticals is developing nedosiran as a treatment for primary hypoxia (PH) types 1 and 2. Patients with this rare disorder produce too much oxalate that forms lots of painful kidney stones.

Image source: Getty Images.

Source Fool.com

Like: 0

DRNA

Share